Table 2. Baseline characteristics of subcohort patients by cinacalcet use, including stratification by baseline iPTH categorya.
| Characteristics (%) | Total (n = 3,276) | |||||||
|---|---|---|---|---|---|---|---|---|
| By baseline iPTH, pg/ml |
|
|||||||
| <300 |
300–<500 |
≥500 |
Total (n = 3,276) | |||||
| Never(n = 1,324) | Ever(n = 624) | Never (n = 404) | Ever(n = 420) | Never (n = 164) | Ever(n = 340) | Never(n = 1,892) | Ever(n = 1,384) | |
| Demographics | ||||||||
| Age, yr | 64.4 (12.8) | 59.1 (11.9) | 64.0 (13.3) | 59.1 (11.9) | 62.6 (12.4) | 58.3 (11.4) | 64.1 (12.9) | 58.9 (11.8) |
| Gender | ||||||||
| Women | 37% | 39% | 37% | 44% | 42% | 38% | 37% | 40% |
| Men | 63% | 61% | 63% | 56% | 58% | 62% | 63% | 60% |
| Renal disease | ||||||||
| Glomerulonephritis | 37% | 50% | 37% | 53% | 57% | 59% | 39% | 53% |
| Diabetic nephropathy | 33% | 19% | 26% | 16% | 16% | 11% | 30% | 16% |
| Other diseases | 30% | 31% | 37% | 31% | 27% | 30% | 31% | 31% |
| Vintage, yr | 5.3 (1.2, 19.8) | 9.7 (2.9, 22.4) | 5.9 (0.9, 18.5) | 11.4 (3.7, 23.5) | 9.5 (1.5, 23.8) | 12.7 (4.5, 25.5) | 5.8 (1.1, 20.0) | 11.0 (3.5, 24.0) |
| Body mass index, kg/m2 | 21.3 (3.6) | 21.5 (3.1) | 21.3 (4.0) | 21.6 (3.5) | 20.9 (3.1) | 21.4 (3.4) | 21.3 (3.6) | 21.5 (3.3) |
| Comorbid conditions | ||||||||
| Cardiovascular | 63% | 57% | 60% | 61% | 61% | 54% | 62% | 57% |
| Coronary artery disease | 27% | 23% | 25% | 23% | 29% | 21% | 27% | 22% |
| Atrial fibrillation | 7% | 5% | 6% | 8% | 11% | 5% | 7% | 6% |
| Other arrhythmia | 13% | 12% | 11% | 15% | 13% | 11% | 12% | 13% |
| Congestive heart failure | 9% | 8% | 10% | 5% | 7% | 5% | 9% | 6% |
| Cerebrovascular disease | 12% | 7% | 14% | 10% | 12% | 10% | 12% | 9% |
| Peripheral vascular disease | 20% | 17% | 19% | 17% | 20% | 16% | 20% | 17% |
| Aortic disease | 8% | 6% | 7% | 6% | 5% | 5% | 7% | 6% |
| Others | 15% | 13% | 14% | 14% | 13% | 15% | 15% | 14% |
| Diabetes mellitus | 41% | 25% | 36% | 22% | 26% | 14% | 39% | 21% |
| Lung disease | 8% | 6% | 7% | 5% | 9% | 9% | 8% | 6% |
| Liver disease | 14% | 12% | 15% | 13% | 15% | 16% | 15% | 13% |
| Malignancy | 5% | 3% | 8% | 5% | 8% | 5% | 6% | 4% |
| History of parathyroidectomy | 4% | 6% | 3% | 10% | 10% | 10% | 4% | 8% |
| Dementia | 4% | 2% | 5% | 2% | 3% | 2% | 4% | 2% |
| Other central nervous disease | 8% | 8% | 9% | 10% | 10% | 10% | 8% | 9% |
| Laboratory measurements and treatment variables | ||||||||
| Serum calciumb, mg/dl | 9.2 (0.8) | 10.0 (0.7) | 9.0 (0.8) | 9.8 (0.7) | 9.3 (1.0) | 9.8 (0.8) | 9.1 (0.8) | 9.9 (0.7) |
| <8.4 mg/dl | 15% | 2% | 19% | 2% | 17% | 3% | 15% | 2% |
| ≥8.4–≤ 10.0 mg/dl | 73% | 54% | 70% | 57% | 62% | 56% | 72% | 55% |
| >10.0 mg/dl | 12% | 44% | 11% | 41% | 21% | 41% | 13% | 43% |
| Serum phosphorus, mg/dl | 5.2 (1.3) | 5.5 (1.2) | 5.6 (1.4) | 5.9 (1.3) | 6.0 (1.6) | 6.2 (1.5) | 5.4 (1.4) | 5.8 (1.3) |
| <3.5 mg/dl | 7% | 4% | 5% | 2% | 2% | 1% | 6% | 3% |
| ≥ 3.5–≤ 6.0 mg/dl | 71% | 66% | 60% | 57% | 49% | 48% | 67% | 59% |
| >6.0 mg/dl | 22% | 30% | 35% | 41% | 49% | 51% | 27% | 38% |
| Serum iPTH, pg/ml | 202 (81, 273) | 218 (118, 285) | 362 (310, 461) | 383 (317, 471) | 681 (517, 1290) | 696 (526, 1149) | 236 (100, 473) | 328 (168, 744) |
| VDRA | ||||||||
| Intravenous | 40% | 58% | 29% | 61% | 54% | 72% | 39% | 63% |
| Oral | 36% | 28% | 37% | 17% | 22% | 7% | 35% | 20% |
| None | 24% | 13% | 34% | 21% | 24% | 21% | 26% | 18% |
| Phosphate binder | ||||||||
| Both | 19% | 33% | 20% | 26% | 23% | 25% | 19% | 29% |
| Calcium-based | 53% | 37% | 51% | 33% | 33% | 28% | 51% | 33% |
| Not calcium-based | 10% | 22% | 8% | 32% | 24% | 38% | 11% | 29% |
| None | 18% | 8% | 21% | 9% | 20% | 9% | 19% | 9% |
| Dialysate calcium | ||||||||
| <3.0 mg/dl | 54% | 50% | 53% | 48% | 54% | 51% | 54% | 50% |
| ≥3.0 mg/dl | 46% | 50% | 47% | 52% | 46% | 49% | 46% | 50% |
| Kt/V | 1.38 (0.3) | 1.46 (0.3) | 1.38 (0.3) | 1.46 (0.3) | 1.47 (0.3) | 1.44 (0.3) | 1.39 (0.3) | 1.46 (0.3) |
| Hemoglobin, g/dl | 10.4 (1.2) | 10.7 (1.2) | 10.5 (1.2) | 10.5 (1.1) | 10.5 (1.3) | 10.5 (1.1) | 10.4 (1.2) | 10.6 (1.1) |
| Serum albumin, g/dl | 3.71 (0.4) | 3.79 (0.4) | 3.73 (0.4) | 3.80 (0.3) | 3.72 (0.4) | 3.80 (0.3) | 3.72 (0.4) | 3.80 (0.3) |
| Serum creatinine, mg/dl | 10.6 (2.9) | 12.0 (2.7) | 10.7 (2.9) | 11.8 (2.7) | 11.0 (2.7) | 12.2 (2.8) | 10.7 (2.9) | 12.0 (2.7) |
| Serum cholesterol, mg/dl | 154 (36) | 155 (36) | 157 (34) | 151 (33) | 156 (35) | 152 (33) | 155 (36) | 153 (34) |
| Serum iron, μg/dl | 58 (33, 96) | 60 (33, 93) | 56 (32, 94) | 58 (34, 93) | 53 (29, 90) | 60 (33, 93) | 57 (32, 95) | 59 (33, 93) |
| Serum ferritin, ng/dl | 126 (23, 412) | 122 (20, 354) | 123 (18, 436) | 117 (18, 397) | 83 (14, 308) | 99 (18, 319) | 121 (21, 408) | 114 (19, 361) |
| Serum CRP, mg/L | 1.1 (0.3, 11) | 1.0 (0.3, 8.5) | 1.1 (0.3, 13) | 1.1 (0.4, 8.4) | 1.5 (0.4, 8.0) | 1.0 (0.3, 8.6) | 1.1 (0.3 11) | 1.0 (0.3, 8.5) |
aMean (SD) are shown for noikrmally distributed data; otherwise, median (p10, p90) are shown for non-normally distributed data.
bCorrected for albumin concentration using modified Payne method.